Evaluation of growth parameters in patients with thalassemia major

Seyed Hessamedin Nabavizadeh1, Amir Anushiravani, Saideh Haghbin

  • 1Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran.

Insights

Children with thalassemia major experience significant growth failure, with a high percentage falling below the 5th percentile for weight, height, and arm circumference compared to healthy peers. Regular monitoring and treatment are crucial for managing this common genetic disorder.

Area of Science:

  • Pediatrics
  • Genetics
  • Hematology

Background:

  • Thalassemia major is a severe, common single-gene disorder causing hemolytic anemia, particularly prevalent in Iran.
  • Growth failure is a significant complication if thalassemia major is not managed effectively.
  • This study addresses the need for thorough investigation of growth parameters in affected children.

Purpose of the Study:

  • To evaluate and compare the physical growth parameters of children with thalassemia major against a control group of healthy children.
  • To identify and quantify growth deficits in thalassemic pediatric patients.

Main Methods:

  • A cross-sectional, descriptive, and analytical study was conducted on 121 pediatric patients with thalassemia major receiving blood transfusion.
  • Physical growth parameters including height, weight, sitting height, and arm circumference were assessed.
  • Data were compared with age, sex, and socioeconomic status-matched healthy children.

Main Results:

  • Significantly higher rates of children with thalassemia major were below the 5th percentile for weight (53.7% vs. 17.1%), height (66.9% vs. 17.1%), and mid-arm circumference (72.7% vs. 32.5%) compared to controls.
  • Statistical analysis confirmed these differences (p < 0.0001 for weight).

Conclusions:

  • Thalassemia major is associated with substantial growth retardation in affected children.
  • Recommendations include regular follow-up appointments with precise intervals for blood transfusions and desferrioxamine (desferal) administration.
  • Effective management is essential to mitigate growth failure complications.
Abstract